Related Experiment Video
Updated: Jan 20, 2026

A Modified Method for Intrathecal Catheterization in Rats
Published on: February 14, 2025
Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS
Sinah Engel1, Michaela Friedrich1, Muthuraman Muthuraman1
1From the Department of Neurology (S.E., M.F., M.M., F.S., S.G., S.B., F.Z., F.L.), Focus Program Translational Neuroscience (FTN), and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University, Mainz; and Institute of Medical Biostatistics (A.P.), Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Objective:
We explored the incremental value of adding multiple disease activity biomarkers in CSF and serum for distinguishing MRI-based benign from aggressive MS in early disease course.
Methods:
Ninety-three patients diagnosed with clinically isolated syndrome (CIS) or early MS were divided into 3 nonoverlapping severity groups defined by objective MRI criteria. Ninety-seven patients with noninflammatory neurologic disorders and 48 patients with other inflammatory neurologic diseases served as controls. Leukocyte subsets in the CSF were analyzed by flow cytometry. CSF neurofilament light chain (NfL) and chitinase-3-like protein 1 (CHI3L1) levels were measured by ELISA. Serum NfL levels were examined using single molecule array technology.
Results:
CSF CD20+/CD14+ ratios and NfL levels in CSF and serum were significantly different between high and low MRI severity groups, whereas no difference was found for CSF CHI3L1 levels. NfL levels in CSF and serum highly correlated. Receiver operating characteristic analysis demonstrated that the cumulative sums combining CSF CD20+/CD14+ ratios and NfL levels in serum or CSF considerably improved diagnostic accuracy. A composite score built from these 2 cumulative sums best distinguished MRI severity. These findings were validated by support vector machine analysis, which confirmed that the accuracy of the cumulative sums and composite score outperforms single biomarkers.
Conclusion:
Patients with extreme manifestations of CIS or early MS defined by strict MRI parameters can be best distinguished by combining markers of intrathecal B-cell accumulation and axonal damage. This could stratify individual treatment decisions toward a more personalized immunotherapy.
Insights
Combining cerebrospinal fluid (CSF) B-cell markers and neurofilament light chain (NfL) in serum or CSF improves the distinction between benign and aggressive multiple sclerosis (MS). This composite score offers personalized treatment strategies for early MS patients.
Area of Science:
- Neuroimmunology
- Biomarker Discovery
- Multiple Sclerosis Pathogenesis
Background:
- Distinguishing between benign and aggressive forms of multiple sclerosis (MS) in its early stages is crucial for effective treatment.
- Current diagnostic methods, including MRI, require complementary biomarkers to accurately assess disease activity and progression.
Purpose of the Study:
- To evaluate the added value of multiple biomarkers in cerebrospinal fluid (CSF) and serum for differentiating MRI-defined benign from aggressive MS.
- To identify a combination of biomarkers that enhances diagnostic accuracy in early MS.
Main Methods:
- Analysis of 93 patients with clinically isolated syndrome (CIS) or early MS, categorized into severity groups based on MRI.
- Flow cytometry for leukocyte subsets, ELISA for CSF neurofilament light chain (NfL) and chitinase-3-like protein 1 (CHI3L1), and single molecule array for serum NfL.
- Receiver operating characteristic and support vector machine analyses to assess diagnostic performance of individual and combined biomarkers.
Main Results:
- CSF CD20+/CD14+ ratios and NfL levels in both CSF and serum were significantly different between high and low MRI severity groups.
- CSF CHI3L1 levels did not show significant differences.
- Combined CSF CD20+/CD14+ ratios and NfL levels (serum or CSF) significantly improved diagnostic accuracy, outperforming single biomarkers.
Conclusions:
- A composite score integrating markers of intrathecal B-cell accumulation and axonal damage (NfL) effectively distinguishes MS severity in early disease stages.
- This combined approach facilitates personalized treatment decisions and immunotherapy strategies for MS patients.
More Related Videos
04:33Author Spotlight: Intrathecal Injection – An Efficient and Reliable Delivery Method to Test the Efficacy of Gene Editing in Neonatal Mouse Brains
Published on: March 8, 2024
05:54Eye-tracking to Distinguish Comprehension-based and Oculomotor-based Regressive Eye Movements During Reading
Published on: October 18, 2018
Related Concept Videos
Aggression
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Secondary Motives: Affiliation Motivation and Aggression Motivation
Neurons: The Axon
The axon attaches to the cell body at a cone-shaped elevation called the axon hillock. The initial part of the axon, closest to the hillock, is known as the initial segment....
Drug Accumulation During Multiple Dosing: Repetitive IV Injections